Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy
Chenwei Pan,1,* Tiaotiao Zhang,2,3,* Shaoxun Li,1,3,* Zhihua Xu,2,3 Binhui Pan,2,3 Sheng Xu,2,3 Shuanghong Jin,1,3 Guangrong Lu,2 Shouxing Yang,2 Zhanxiong Xue,2 Ping Chen,4 Xian Shen,5 Fangyan Wang,6 Changlong Xu2,7 1Department of Infectious Disease, Second Affiliated Hospital and Yuying Children&a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/59eef45e92c945498fd61626b92a6e41 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:59eef45e92c945498fd61626b92a6e41 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:59eef45e92c945498fd61626b92a6e412021-12-02T14:40:41ZHybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy1178-2013https://doaj.org/article/59eef45e92c945498fd61626b92a6e412021-03-01T00:00:00Zhttps://www.dovepress.com/hybrid-nanoparticles-modified-by-hyaluronic-acid-loading-an-hsp90-inhi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Chenwei Pan,1,* Tiaotiao Zhang,2,3,* Shaoxun Li,1,3,* Zhihua Xu,2,3 Binhui Pan,2,3 Sheng Xu,2,3 Shuanghong Jin,1,3 Guangrong Lu,2 Shouxing Yang,2 Zhanxiong Xue,2 Ping Chen,4 Xian Shen,5 Fangyan Wang,6 Changlong Xu2,7 1Department of Infectious Disease, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Gastroenterology, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 3Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 4Department of Infectious Disease, Shulan Hospital, Hangzhou, Zhejiang, 310012, People’s Republic of China; 5Department of Gastrointestinal Surgery, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 6Department of Pathophysiology, School of Basic Medicine Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 7Center for Diagnostics and Therapeutics, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30302, USA*These authors contributed equally to this workCorrespondence: Fangyan Wang; Changlong Xu Email wzyxywfy@126.com; xchlong@163.comBackground: As a therapeutic target for cancer treatment, HSP90 has been explored extensively. However, the significant side effects of the HSP90 inhibitor 17AAG have limited its clinical use.Methods: In this study, we used hyaluronic acid (HA)–decorated DOTAP–PLGA hybrid nanoparticles (HA-DOTAP-PLGA NPs) as 17AAG-delivery carriers for targeted colon cancer therapy.Results: Different methods were used to characterize the successful fabrication of these hybrid PLGA NPs. Our results demonstrated that internalization of HA-NPs in colon cancer cells was governed by CD44receptor–mediated endocytosis. Annexin V–propidium iodide staining experiments revealed that cell apoptosis induced by HA-NPs-17AAG in colon cancer cells was more efficient than free 17AAG. In two animal models used to screen anticancer efficacy (Luc-HT29 subcutaneous xenograft and AOM/DSS-induced orthotopic tumor model), HA-NPs-17AAG significantly inhibited xenograft and orthotopic tumor growth, demonstrating HA-NPs-17AAG had much better therapeutic efficiency than free 17AAG. It is worth noting that great biocompatibility of HA-DOTAP-PLGA NPs was observed both in vitro and in vivo.Conclusion: Our research offers a preclinical proof of concept for colon cancer therapy with DOTAP-PLGA NPs as a creative drug-delivery system.Keywords: cationic hybrid nanoparticles, hyaluronic acid, HA, HSP90 inhibitor, colon cancer, targeted delivery systemPan CZhang TLi SXu ZPan BXu SJin SLu GYang SXue ZChen PShen XWang FXu CDove Medical Pressarticlecationic hybrid nanoparticleshyaluronic acid (ha)hsp90 inhibitorcolon cancertargeted delivery systemMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1743-1755 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
cationic hybrid nanoparticles hyaluronic acid (ha) hsp90 inhibitor colon cancer targeted delivery system Medicine (General) R5-920 |
| spellingShingle |
cationic hybrid nanoparticles hyaluronic acid (ha) hsp90 inhibitor colon cancer targeted delivery system Medicine (General) R5-920 Pan C Zhang T Li S Xu Z Pan B Xu S Jin S Lu G Yang S Xue Z Chen P Shen X Wang F Xu C Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| description |
Chenwei Pan,1,* Tiaotiao Zhang,2,3,* Shaoxun Li,1,3,* Zhihua Xu,2,3 Binhui Pan,2,3 Sheng Xu,2,3 Shuanghong Jin,1,3 Guangrong Lu,2 Shouxing Yang,2 Zhanxiong Xue,2 Ping Chen,4 Xian Shen,5 Fangyan Wang,6 Changlong Xu2,7 1Department of Infectious Disease, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Gastroenterology, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 3Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 4Department of Infectious Disease, Shulan Hospital, Hangzhou, Zhejiang, 310012, People’s Republic of China; 5Department of Gastrointestinal Surgery, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 6Department of Pathophysiology, School of Basic Medicine Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 7Center for Diagnostics and Therapeutics, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30302, USA*These authors contributed equally to this workCorrespondence: Fangyan Wang; Changlong Xu Email wzyxywfy@126.com; xchlong@163.comBackground: As a therapeutic target for cancer treatment, HSP90 has been explored extensively. However, the significant side effects of the HSP90 inhibitor 17AAG have limited its clinical use.Methods: In this study, we used hyaluronic acid (HA)–decorated DOTAP–PLGA hybrid nanoparticles (HA-DOTAP-PLGA NPs) as 17AAG-delivery carriers for targeted colon cancer therapy.Results: Different methods were used to characterize the successful fabrication of these hybrid PLGA NPs. Our results demonstrated that internalization of HA-NPs in colon cancer cells was governed by CD44receptor–mediated endocytosis. Annexin V–propidium iodide staining experiments revealed that cell apoptosis induced by HA-NPs-17AAG in colon cancer cells was more efficient than free 17AAG. In two animal models used to screen anticancer efficacy (Luc-HT29 subcutaneous xenograft and AOM/DSS-induced orthotopic tumor model), HA-NPs-17AAG significantly inhibited xenograft and orthotopic tumor growth, demonstrating HA-NPs-17AAG had much better therapeutic efficiency than free 17AAG. It is worth noting that great biocompatibility of HA-DOTAP-PLGA NPs was observed both in vitro and in vivo.Conclusion: Our research offers a preclinical proof of concept for colon cancer therapy with DOTAP-PLGA NPs as a creative drug-delivery system.Keywords: cationic hybrid nanoparticles, hyaluronic acid, HA, HSP90 inhibitor, colon cancer, targeted delivery system |
| format |
article |
| author |
Pan C Zhang T Li S Xu Z Pan B Xu S Jin S Lu G Yang S Xue Z Chen P Shen X Wang F Xu C |
| author_facet |
Pan C Zhang T Li S Xu Z Pan B Xu S Jin S Lu G Yang S Xue Z Chen P Shen X Wang F Xu C |
| author_sort |
Pan C |
| title |
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| title_short |
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| title_full |
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| title_fullStr |
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| title_full_unstemmed |
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy |
| title_sort |
hybrid nanoparticles modified by hyaluronic acid loading an hsp90 inhibitor as a novel delivery system for subcutaneous and orthotopic colon cancer therapy |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/59eef45e92c945498fd61626b92a6e41 |
| work_keys_str_mv |
AT panc hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT zhangt hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT lis hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT xuz hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT panb hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT xus hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT jins hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT lug hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT yangs hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT xuez hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT chenp hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT shenx hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT wangf hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy AT xuc hybridnanoparticlesmodifiedbyhyaluronicacidloadinganhsp90inhibitorasanoveldeliverysystemforsubcutaneousandorthotopiccoloncancertherapy |
| _version_ |
1718390175015370752 |